Glenmark Recalls Products in US for Manufacturing Issues

By By Rediff Money Desk, New Delhi
Oct 13, 2024 12:06
Glenmark Pharmaceuticals is recalling two products in the US, Ryaltris Nasal Spray and Ciclopirox Gel, due to manufacturing defects. The USFDA has classified the recalls as Class II and Class III.
New Delhi, Oct 13 (PTI) Drug firm Glenmark is recalling two products in the US due to manufacturing issues, according to the US Food and Drug Administration.

New Jersey-based Glenmark Pharmaceuticals Inc, USA, a unit of Mumbai-based Glenmark Pharmaceuticals, is recalling 45,504 bottles of Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray.

The company is recalling the affected lot due to "defective delivery system", the US Food and Drug Administration (USFDA) said in its latest enforcement report.

"The dip tube is clogged causing the spray not to work," it added.

Glenmark Pharmaceuticals Inc, USA, initiated the nationwide (US) Class II recall on September 24 this year.

As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

The US health regulator said the drug firm is also recalling a generic medication to treat certain fungal skin infections.

Glenmark Pharmaceuticals Inc, US, is recalling 11,568 tubes of Ciclopirox Gel, produced at the company's Goa-based plant, due to "defective container"," USFDA stated.

Firm received complaints of broken tubes at the seal, it added.

The company initiated the Class III recall on September 30.

As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".

India has the highest number of USFDA-compliant companies with plants outside the US.

The country is the largest supplier of generic medicines with around 20 per cent share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic categories.

The products manufactured in the country are shipped to over 200 countries around the globe, with Japan, Australia, West Europe, and the US as the main destinations.
Source: PTI
Read More On:
glenmarkdrug recallusfdaryaltrisciclopirox gel
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

DRI Seizes Red Sanders Worth Rs 6.26 Cr, 4...

DRI seizes 15 MT of red sanders worth Rs 6.26 crore in Delhi, arrests 4. Illegal export...

UAE Fund to Invest ₹1,000 Cr in Kerala Startups

UAE-based Feeder Fund to invest ₹1,000 crore in Kerala startups over 3 years. Boost...

ECL Aims for 58 MT Output, Mine Closures Planned

Eastern Coalfields Ltd (ECL) targets 58 MT output, plans closure of six underground...

India: Export Potential in Russia

300 Indian products have huge export potential in Russia. Engineering, pharma, agri,...

Gold & Silver Rally: Inflation Data in Focus

Gold and silver prices rally amid inflation data focus. Analysts eye central bank...

India Ranks 3rd in Global AI Vibrancy Index

India ranks 3rd in Stanford University's Global AI Vibrancy tool, surpassing advanced...

EPFOA Urges CPFC: Equip Offices for Compliance

EPFOA urges CPFC to equip field offices with authority & tools to handle default &...

TV Prices to Rise in January: Chip Shortage &...

TV prices are expected to increase in January due to memory chip shortages and a...

India Gems & Jewellery Exports Up 20% in November

India's gems and jewellery exports grew 20% to USD 2.5 billion in November, says GJEPC....

Navi Mumbai Airport: 3rd Runway Feasibility Study

CIDCO invites bids for a consultant to study the feasibility of a third runway at Navi...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com